Johnson & Johnson (FRA:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 418.20B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 19.47 |
| Forward PE | 18.00 |
| Dividend | 4.57 (2.60%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 210 |
| Average Volume | 502 |
| Open | 172.62 |
| Previous Close | 173.50 |
| Day's Range | 172.62 - 174.34 |
| 52-Week Range | 129.00 - 180.12 |
| Beta | n/a |
| RSI | 55.21 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
3 Dividend Stocks Wall Street is Piling Into Before 2026
There is an apparent shift in how Wall Street views the stock market, as retail investors are increasingly doubting the AI rally. This is causing investors to pile into dividend stocks like Johnson & ...
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate ...
Notable ETF Inflow Detected - XLV, JNJ, ABBV, MRK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
Snatch This Bargain Even Cheaper Than Director Morikis Did
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 26, Johnson & Johnson's Director, John G. Morik...
Barclays Raises Price Target for Johnson & Johnson (JNJ) to $197 | JNJ Stock News
Barclays Raises Price Target for Johnson & Johnson (JNJ) to $197 | JNJ Stock News
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform , with an increased price forecast from $4 to $7. The company is evolving beyond neurology and...
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this cust...
16 Quality Stocks to Own for a Volatile Market
The S&P 500 has staged an impressive rebound, but is in for more swings.
Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-t...
2 Top Dividend Stocks to Buy and Hold
Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
Wasatch Global Value Fund Q3 2025 Performance Review
The Wasatch Global Value Fund - Investor Class gained 6.36% in the third quarter of 2025, outperforming the MSCI All Country World Value Index, which added 6.13%. Leading contributors to the Fund's pe...
IHE: Pharma Powerhouse ETF Despite High Fees And Valuation
iShares U.S. Pharmaceuticals ETF offers growth and dividends from top holdings like LLY, JNJ, MRK with strong earnings and sector focus. See why IHE ETF is a buy.
3 Superb Dividend Stocks to Hold for the Next 20 Years
Johnson & Johnson is a financial fortress with a solid pipeline and portfolio. Coca-Cola has an asset-light model that drives its profitability.
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.
What's Going On With Johnson & Johnson Stock On Wednesday?
Johnson & Johnson (NYSE: JNJ) stock has surged almost 42.9% in the year to date, approximately 35% in 6 months, and 8.6% in one month. JNJ is trading at elevated levels. See what the experts say here...
JNJ a Top 25 Dividend Giant With $73.76B Held By ETFs
Johnson & Johnson (Symbol: JNJ) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a staggering $73.76B worth of stock held by ETFs, and above-average ''DividendRank'' statistics inclu...
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by...
Johnson & Johnson Reaches Analyst Target Price
In recent trading, shares of Johnson & Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $203.50, changing hands for $203.90/share. When a stock reaches the target ...
Johnson & Johnson To Discontinue Autonomy Study
(RTTNews) - Johnson & Johnson has decided to discontinue the Autonomy study as a scheduled review found posdinemab did not achieve statistical significance in slowing clinical decline. The Autonomy pr...
1 Reason Why Shares of Johnson & Johnson Are Surging This Month
A spate of promising news is helping to extend a post-earnings rally for the healthcare giant's shares.
Johnson & Johnson (JNJ) Notable in Active Option Trading
Johnson & Johnson (JNJ) Notable in Active Option Trading